Cargando…

Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats

PURPOSE: Kv1.3 channel regulates the activity of lymphocytes, macrophages, or adipose tissue and its blockade reduces inflammatory cytokine secretion and improves insulin sensitivity in animals with metabolic syndrome and in genetically obese mice. Thus, Kv1.3 blockade could be a strategy for the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zayas-Arrabal, Julián, Alquiza, Amaia, Rodríguez-de-Yurre, Ainhoa, Echeazarra, Leyre, Fernández-López, Víctor, Gallego, Mónica, Casis, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834174/
https://www.ncbi.nlm.nih.gov/pubmed/34623540
http://dx.doi.org/10.1007/s10557-021-07264-1
_version_ 1784868403318620160
author Zayas-Arrabal, Julián
Alquiza, Amaia
Rodríguez-de-Yurre, Ainhoa
Echeazarra, Leyre
Fernández-López, Víctor
Gallego, Mónica
Casis, Oscar
author_facet Zayas-Arrabal, Julián
Alquiza, Amaia
Rodríguez-de-Yurre, Ainhoa
Echeazarra, Leyre
Fernández-López, Víctor
Gallego, Mónica
Casis, Oscar
author_sort Zayas-Arrabal, Julián
collection PubMed
description PURPOSE: Kv1.3 channel regulates the activity of lymphocytes, macrophages, or adipose tissue and its blockade reduces inflammatory cytokine secretion and improves insulin sensitivity in animals with metabolic syndrome and in genetically obese mice. Thus, Kv1.3 blockade could be a strategy for the treatment of type 2 diabetes. Elevated circulating levels of TNFα and IL-1b mediate the higher susceptibility to cardiac arrhythmia in type 2 diabetic rats. We hypothesized that Kv1.3 channel blockade with the psoralen PAP1 could have immunomodulatory properties that prevent QTc prolongation and reduce the risk of arrhythmia in type 2 diabetic rats. METHODS: Type 2 diabetes was induced to Sprague-Dawley rats by high-fat diet and streptozotocin injection. Diabetic animals were untreated, treated with metformin, or treated with PAP1 for 4 weeks. Plasma glucose, insulin, cholesterol, triglycerides, and cytokine levels were measured using commercial kits. ECG were recorded weekly, and an arrhythmia-inducing protocol was performed at the end of the experimental period. Action potentials were recorded in isolated ventricular cardiomyocytes. RESULTS: In diabetic animals, PAP1 normalized glycaemia, insulin resistance, adiposity, and lipid profile. In addition, PAP1 prevented the diabetes-induced repolarization defects through reducing the secretion of the inflammatory cytokines IL-10, IL-12p70, GM-CSF, IFNγ, and TNFα. Moreover, compared to diabetic untreated and metformin-treated animals, those treated with PAP1 had the lowest risk of developing the life-threatening arrhythmia Torsade de Pointes under cardiac challenge. CONCLUSION: Kv1.3 inhibition improves diabetes and diabetes-associated low-grade inflammation and cardiac electrical remodeling, resulting in more protection against cardiac arrhythmia compared to metformin. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10557-021-07264-1.
format Online
Article
Text
id pubmed-9834174
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-98341742023-01-13 Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats Zayas-Arrabal, Julián Alquiza, Amaia Rodríguez-de-Yurre, Ainhoa Echeazarra, Leyre Fernández-López, Víctor Gallego, Mónica Casis, Oscar Cardiovasc Drugs Ther Original Article PURPOSE: Kv1.3 channel regulates the activity of lymphocytes, macrophages, or adipose tissue and its blockade reduces inflammatory cytokine secretion and improves insulin sensitivity in animals with metabolic syndrome and in genetically obese mice. Thus, Kv1.3 blockade could be a strategy for the treatment of type 2 diabetes. Elevated circulating levels of TNFα and IL-1b mediate the higher susceptibility to cardiac arrhythmia in type 2 diabetic rats. We hypothesized that Kv1.3 channel blockade with the psoralen PAP1 could have immunomodulatory properties that prevent QTc prolongation and reduce the risk of arrhythmia in type 2 diabetic rats. METHODS: Type 2 diabetes was induced to Sprague-Dawley rats by high-fat diet and streptozotocin injection. Diabetic animals were untreated, treated with metformin, or treated with PAP1 for 4 weeks. Plasma glucose, insulin, cholesterol, triglycerides, and cytokine levels were measured using commercial kits. ECG were recorded weekly, and an arrhythmia-inducing protocol was performed at the end of the experimental period. Action potentials were recorded in isolated ventricular cardiomyocytes. RESULTS: In diabetic animals, PAP1 normalized glycaemia, insulin resistance, adiposity, and lipid profile. In addition, PAP1 prevented the diabetes-induced repolarization defects through reducing the secretion of the inflammatory cytokines IL-10, IL-12p70, GM-CSF, IFNγ, and TNFα. Moreover, compared to diabetic untreated and metformin-treated animals, those treated with PAP1 had the lowest risk of developing the life-threatening arrhythmia Torsade de Pointes under cardiac challenge. CONCLUSION: Kv1.3 inhibition improves diabetes and diabetes-associated low-grade inflammation and cardiac electrical remodeling, resulting in more protection against cardiac arrhythmia compared to metformin. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10557-021-07264-1. Springer US 2021-10-08 2023 /pmc/articles/PMC9834174/ /pubmed/34623540 http://dx.doi.org/10.1007/s10557-021-07264-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Zayas-Arrabal, Julián
Alquiza, Amaia
Rodríguez-de-Yurre, Ainhoa
Echeazarra, Leyre
Fernández-López, Víctor
Gallego, Mónica
Casis, Oscar
Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats
title Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats
title_full Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats
title_fullStr Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats
title_full_unstemmed Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats
title_short Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats
title_sort kv1.3 channel blockade improves inflammatory profile, reduces cardiac electrical remodeling, and prevents arrhythmia in type 2 diabetic rats
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834174/
https://www.ncbi.nlm.nih.gov/pubmed/34623540
http://dx.doi.org/10.1007/s10557-021-07264-1
work_keys_str_mv AT zayasarrabaljulian kv13channelblockadeimprovesinflammatoryprofilereducescardiacelectricalremodelingandpreventsarrhythmiaintype2diabeticrats
AT alquizaamaia kv13channelblockadeimprovesinflammatoryprofilereducescardiacelectricalremodelingandpreventsarrhythmiaintype2diabeticrats
AT rodriguezdeyurreainhoa kv13channelblockadeimprovesinflammatoryprofilereducescardiacelectricalremodelingandpreventsarrhythmiaintype2diabeticrats
AT echeazarraleyre kv13channelblockadeimprovesinflammatoryprofilereducescardiacelectricalremodelingandpreventsarrhythmiaintype2diabeticrats
AT fernandezlopezvictor kv13channelblockadeimprovesinflammatoryprofilereducescardiacelectricalremodelingandpreventsarrhythmiaintype2diabeticrats
AT gallegomonica kv13channelblockadeimprovesinflammatoryprofilereducescardiacelectricalremodelingandpreventsarrhythmiaintype2diabeticrats
AT casisoscar kv13channelblockadeimprovesinflammatoryprofilereducescardiacelectricalremodelingandpreventsarrhythmiaintype2diabeticrats